The FNR and Fondation Cancer have signed a multi-year collaboration agreement from 2020 to 2023, aimed at developing and intensifying cooperation. In this context, four cancer research projects were selected for funding in 2020, a total commitment of 2.8 MEUR.
In 2021, there will be a number of changes coming to FNR funding policies, affecting most of our diverse selection of programmes. These changes represent a forward evolution for the FNR, as they align with international best practices meant to improve the quality of science and research on a systemic level. A recording and the presentations from the webinar held on 13 January are now available, as well as an FAQ.
PRIMA, the Partnership on Research and Innovation in the Mediterranean Area has launched its 2021 transnational Call for pre-proposals to 21 April 2021, 17:00 CET.
Using solar absorbers for collection and storage of heat from the sun is an environmentally friendly way to generate heat, yet only 16% of heating is generated from renewable energy. Material scientists are looking for ways to boost this number by making the solar absorber coatings more efficient.
Luxembourg start-up LuxAI, with their socially assistive robot QTrobot, has been making waves on an international level since it was created. The FNR has supported the project from its inception through the development of a prototype, helping bridge the gap between lab and commercialisation. We speak to LuxAI founders Dr Pouyan Ziafati and Dr Aida Nazarikhorram about the LuxAI journey so far; how QTrobot came to be and how parents can now have a QTrobot at home.
Carbs are all around us: a major constituent in food, they also play a role in many biological processes such as intercellular communication; they are in demand in the pharmaceutical industry, where they are currently used as anticoagulants and in skincare. With the goal of no longer having to rely solely on nature’s production of carbs, scientists have been working on ways to ramp up production. A case for chemistry!
Neurogenerative diseases and cancer affect millions of people worldwide, especially people over 60. While advances in diagnosis and treatment have been made, there are still many open questions on the path to better treatment and earlier diagnosis. Translational neuroscientist Pauline Mencke studies a gene that is involved both in Parkinson’s disease and the brain cancer Glioblastoma multiforme.